[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study

Overview

Journal Theranostics

Date 2016 Mar 5

PMID 26941843

Citations 38

Authors

Richard P Baum

Andreas W Kluge

Harshad Kulkarni

Ulrike Schorr-Neufing

Karin Niepsch

Norman Bitterlich

Cees J A van Echteld

Affiliations

Soon will be listed here.

Abstract

Purpose: To characterise efficacy and safety of (177)Lu-DOTATOC as agent for peptide receptor radiotherapy (PRRT) of advanced neuroendocrine tumours (NET).

Patients And Methods: Fifty-six subjects with metastasized and progressive NET (50% gastroenteral, 26.8% pancreatic, 23.2% other primary sites) treated consecutively with (177)Lu-DOTATOC were analysed retrospectively. Subjects were administered (177)Lu-DOTATOC (mean 2.1 cycles; range 1-4) as 7.0GBq (median) doses at three-monthly intervals. Efficacy was analysed using CT and/or MRI according to RECIST 1.1 criteria and results were stratified for the number of administered cycles and the primary tumour origin.

Results: In the total NET population (A), median progression-free (PFS) and overall survival (OS) were 17.4 and 34.2 months, respectively, assessed in a follow-up time (mean ± SD) of 16.1 ± 12.4 months. In patients receiving more than one cycle, mean follow-up time was 22.4 ± 11.0 months for all NETs (B) and PFS was 32.0 months for all NETs (B), 34.5 months for GEP-NET (C), and 11.9 months for other NETs (D). Objective response rates (Complete/Partial Responses) were 33.9%, 40.6%, 54.2%, and 0% for A, B, C, and D groups, respectively, while disease control rates in the same were 66.1%, 93.8%, 100%, and 75%. Complete responses (16.1%, 18.8% and 25.0% for groups A, B and C) were high, 78% of which were maintained throughout the follow up. There were no serious adverse events. One case of self-limiting grade 3 myelotoxicity was reported. Although 20% of patients had mild renal insufficiency at baseline, there was no evidence of exacerbated or de novo renal toxicity after treatment.

Conclusion: (177)Lu-DOTATOC is a novel agent for PRRT with major potential to induce objective tumour responses and sustained disease control in progressive neuroendocrine tumours, even when administered in moderate activities. The observed safety profile suggests a particularly favourable therapeutic index, including in patients with impaired bone marrow or renal function, which reflects a uniquely low uptake of (177)Lu-DOTATOC by normal organs.

Citing Articles

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using Lu-iPSMA and Lu-DOTATOC: Experience after 905 Treatment Doses.

Luna-Gutierrez M, Hernandez-Ramirez R, Soto-Abundiz A, Garcia-Perez O, Ancira-Cortez A, Lopez-Buenrostro S Pharmaceutics. 2023; 15(7).

PMID: 37514174 PMC: 10386094. DOI: 10.3390/pharmaceutics15071988.

Application of nano-radiosensitizers in combination cancer therapy.

Varzandeh M, Sabouri L, Mansouri V, Gharibshahian M, Beheshtizadeh N, Hamblin M Bioeng Transl Med. 2023; 8(3):e10498.

PMID: 37206240 PMC: 10189501. DOI: 10.1002/btm2.10498.

Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of Tb into the Clinic.

Favaretto C, Grundler P, Talip Z, Landolt S, Sepini L, Koster U J Nucl Med. 2023; 64(7):1138-1144.

PMID: 37201956 PMC: 10315698. DOI: 10.2967/jnumed.122.265268.

Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic.

Rubira L, Deshayes E, Santoro L, Kotzki P, Fersing C Pharmaceutics. 2023; 15(4).

PMID: 37111537 PMC: 10146019. DOI: 10.3390/pharmaceutics15041051.

Preclinical Evaluation of [Tb]Tb-Crown-TATE-A Novel SPECT Imaging Theranostic Agent Targeting Neuroendocrine Tumours.

Wharton L, McNeil S, Merkens H, Yuan Z, Van de Voorde M, Engudar G Molecules. 2023; 28(7).

PMID: 37049918 PMC: 10095901. DOI: 10.3390/molecules28073155.

References

Reubi J, Schar J, Waser B, Wenger S, Heppeler A, Schmitt J . Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27(3):273-82. DOI: 10.1007/s002590050034. View

Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E . 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 2014; 41(10):1845-51. DOI: 10.1007/s00259-014-2735-5. View

Reubi J, Waser B . Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003; 30(5):781-93. DOI: 10.1007/s00259-003-1184-3. View

Eshima D, Taylor Jr A . Technetium-99m (99mTc) mercaptoacetyltriglycine: update on the new 99mTc renal tubular function agent. Semin Nucl Med. 1992; 22(2):61-73. DOI: 10.1016/s0001-2998(05)80082-0. View

Forrer F, Uusijarvi H, Storch D, Maecke H, Mueller-Brand J . Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med. 2005; 46(8):1310-6. View

Esser J, Krenning E, Teunissen J, Kooij P, van Gameren A, Bakker W . Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?. Eur J Nucl Med Mol Imaging. 2006; 33(11):1346-51. DOI: 10.1007/s00259-006-0172-9. View

Kwekkeboom D, de Herder W, Kam B, Van Eijck C, Van Essen M, Kooij P . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13):2124-30. DOI: 10.1200/JCO.2007.15.2553. View

Yao J, Phan A, Chang D, Wolff R, Hess K, Gupta S . Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008; 26(26):4311-8. PMC: 2653122. DOI: 10.1200/JCO.2008.16.7858. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

10.

Rinke A, Muller H, Schade-Brittinger C, Klose K, Barth P, Wied M . Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27(28):4656-63. DOI: 10.1200/JCO.2009.22.8510. View

11.

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

12.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H . Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011; 29(17):2416-23. DOI: 10.1200/JCO.2010.33.7873. View

13.

Fizazi K, Greco F, Pavlidis N, Pentheroudakis G . Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011; 22 Suppl 6:vi64-8. DOI: 10.1093/annonc/mdr389. View

14.

Bodei L, Cremonesi M, Grana C, Fazio N, Iodice S, Baio S . Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011; 38(12):2125-35. DOI: 10.1007/s00259-011-1902-1. View

15.

Poeppel T, Binse I, Petersenn S, Lahner H, Schott M, Antoch G . 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011; 52(12):1864-70. DOI: 10.2967/jnumed.111.091165. View

16.

Schuchardt C, Kulkarni H, Prasad V, Zachert C, Muller D, Baum R . The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC. Recent Results Cancer Res. 2012; 194:519-36. DOI: 10.1007/978-3-642-27994-2_30. View

17.

Kulkarni H, Schuchardt C, Baum R . Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient. Recent Results Cancer Res. 2012; 194:551-9. DOI: 10.1007/978-3-642-27994-2_32. View

18.

Oberg K, Knigge U, Kwekkeboom D, Perren A . Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii124-30. DOI: 10.1093/annonc/mds295. View

19.

Bodei L, Mueller-Brand J, Baum R, Pavel M, Horsch D, ODorisio M . The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013; 40(5):800-16. PMC: 3622744. DOI: 10.1007/s00259-012-2330-6. View

20.

Vinjamuri S, Gilbert T, Banks M, McKane G, Maltby P, Poston G . Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. Br J Cancer. 2013; 108(7):1440-8. PMC: 3629418. DOI: 10.1038/bjc.2013.103. View